Praxis Precision Medicines (PRAX) Stock Surges on FDA Progress and Epilepsy Trial Wins: Latest News and 2026 Forecast
Praxis Precision Medicines shares traded around $189.97 early December 5 after surging on positive FDA feedback for its essential tremor drug and new data in rare epilepsies. The stock swung between $180.25 and $305.55 intraday, with a market cap near $1.1 billion. PRAX has gained over 1,700% in 12 months, but remains volatile amid short-seller pressure and ongoing losses.